Intravitreal Anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 7, 2012, Pages 4323-4328

  Nakao, Shintaro ^a   Arima, Mitsuru ^a   Ishikawa, Keijiro ^a   Kohno, Riichiro ^a   Kawahara, Shuhei ^a   Miyazaki, Masanori ^a   Yoshida, Shigeo ^a   Enaida, Hiroshi ^a   Hafezi Moghadam, Ali ^b,c   Kono, Toshihiro ^d   Ishibashi, Tatsuro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Fukuoka University Chikushi Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD45 ANTIGEN; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LEUKOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINITIS; ANIMAL; C57BL MOUSE; CELL MOTION; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; INFLAMMATION; INTRAVITREAL DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; NEWBORN; PATHOLOGY; RETINA; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL MOVEMENT; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; RETINA; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866276458     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-9119     Document Type: Article

References (24)

1. Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol. 2010;2010:201026
2. Nakao S, Kuwano T, Tsutsumi-Miyahara C, et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 betainduced neovascularization and tumor growth. J Clin Invest. 2005;115:2979-2991
3. Yoshida S, Yoshida A, Ishibashi T, Elner SG, Elner VM. Role of MCP-1 and MIP-1alpha in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization. J Leukoc Biol. 2003;73:137-144
4. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363-365
5. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461
6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331:1480-1487
7. Sawano A, Iwai S, Sakurai Y, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. 2001;97: 785-791
8. Kohno R, Hata Y, Mochizuki Y, et al. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol. 2010;150:223-229
9. Enaida H, Okamoto K, Fujii H, Ishibashi T. LSFG findings of proliferative diabetic retinopathy after intravitreal injection of bevacizumab. Ophthalmic Surg Lasers Imaging. 2010;41: Online: e1-3
10. Harada C, Okumura A, Namekata K, et al. Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2006;74:249-256
11. Kase S, Saito W, Ohno S, Ishida S. Proliferative diabetic retinopathy with lymphocyte-rich epiretinal membrane associated with poor visual prognosis. Invest Ophthalmol Vis Sci. 2009;50:5909-5912
12. Georgopoulos M, Polak K, Prager F, Prunte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93:457-462
13. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152:266-272
14. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4:1565-1573
15. Ishikawa K, Yoshida S, Nakao S, et al. Bone marrow-derived monocyte lineage cells recruited by MIP-1beta promote physiological revascularization in mouse model of oxygeninduced retinopathy. Lab Invest. 2012;92:91-101
16. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198:483-489
17. Nakao S, Noda K, Zandi S, et al. VAP-1-mediated M2 macrophage infiltration underlies IL-1beta- but not VEGF-Ainduced lymph- and angiogenesis. Am J Pathol. 2011;178: 1913-1921
18. Nakao S, Zandi S, Lara-Castillo N, Taher M, Ishibashi T, Hafezi- Moghadam A. Larger therapeutic window for steroid vs VEGFA inhibitor in inflammatory angiogenesis: surprisingly similar impact on leukocyte infiltration. Invest Ophthalmol Vis Sci. 2012;53:3296-3302
19. Tatar O, Yoeruek E, Szurman P, et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol. 2008;126:782-790
20. Kezic J, McMenamin PG. Differential turnover rates of monocyte-derived cells in varied ocular tissue microenvironments. J Leukoc Biol. 2008;84:721-729
21. Koto T, Takubo K, Ishida S, et al. Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol. 2007; 170:1389-1397
22. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158:147-152
23. Hori J, Vega JL, Masli S. Review of ocular immune privilege in the year 2010: modifying the immune privilege of the eye. Ocul Immunol Inflamm. 2010;18:325-333
24. Kataoka K, Nishiguchi KM, Kaneko H, van Rooijen N, Kachi S, Terasaki H. The roles of vitreal macrophages and circulating leukocytes in retinal neovascularization. Invest Ophthalmol Vis Sci. 2011;52:1431-1438.